CDK-IN-18
CDK-IN-18 (Compound EX.161) is an orally active, brain-penetrant and selective inhibitor of CDK2, CDK4, and CDK6. CDK-IN-18 inhibits the activity of cyclin-CDK complexes, blocks phosphorylation of the retinoblastoma protein (pRb), arresting the cell cycle transition from G1 to S phase. CDK-IN-18 is promising for research of cancers, such as breast cancer (especially hormone receptor-positive, HER2-negative type), lung cancer, and colorectal cancer[1][2].
Product Specifications
CAS Number
2531743-46-9
UNSPSC
12352005
Target
CDK
Related Pathways
Cell Cycle/DNA Damage
Field of Research
Cancer
Smiles
CC(C1=C2N(N=C1)C=CC(C3=NC(NC4=CC=C(N5C(C[C@H](CC5)N(C)C)=O)C=N4)=NC=C3)=C2)C
Molecular Formula
C26H30N8O
Molecular Weight
470.57
References & Citations
[1]Zhilong Hu, et al. Cdk inhibitors. WO2020224568A1. 2020-11-12.|[2]Xiaotian Zhu, et al. Salt and solid forms of a cdk inhibitor. WO2025103447A1. 2025-05-22.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CDK2; CDK4; CDK6
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
041216-HRP 200 µL
RPL5, NT (RPL5, 60S ribosomal protein L5) (Azide free) (HRP) discontinued
Sign In for Pricing
View Details